The engagement of leukocyte Fcγ receptors by antibody‐antigen complexes leads to an enhanced antibody‐dependent, cell‐mediated cytotoxicity (ADCC) 40, which can interact more efficiently with the DR5 agonistic antibody drozitumab when compared to artificial Fc crosslinking in vitro, leading to improved cytotoxicity against the human osteosarcoma in the tibia and lungs of the mice. The gene discussed is TNFRSF10B; the disease is osteosarcoma.